Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase NA 3Phase 3 2Phase 2 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Gastrointestinal 6Thoracic 5CNS 4Other hematologic neoplasm 3Dermatologic 3Head & Neck 2Genitourinary 2Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1Lower Urinary Tract Symptoms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Sodium Chloride × Genitourinary × Clear all
NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Bayer

Phase 2 Completed
64 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00681148 2013-11-21

Botulinum Toxin Injection With Prostate Brachytherapy

Emory University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡